In addition, AML patients with higher Rheb1 expression showed reduced survival (median survival: 8.47 months) compared with patients with lower Rheb1 expression (median survival: 11.47 months) based on the Leukemia Gene Atlas (LGA) analysis (http://www.leukemia-gene-atlas.org/LGAtlas/LGAtlas.html#aboutUs) (Additional file 1: Figure S1A) [30]. Here, RHEBP1 is linked to leukemia.